The use of platelet integrin alpha(2b)beta(3) inhibitors in thrombosis, although clinically effective, has been limited by an associated high risk of bleeding. Now, researchers at the University of Illinois at Chicago have developed an integrin alpha(2b)beta(3) inhibitor that suppresses arterial thrombosis without triggering bleeding in mice.